Esperion Therapeutics, Inc Has Bullish Trade, Bb Biotech Ag Bought Stake!

February 15, 2018 - By Clifton Ray

 Esperion Therapeutics, Inc Has Bullish Trade, Bb Biotech Ag Bought Stake!

Investors sentiment increased to 1.67 in Q3 2017. Its up 0.45, from 1.22 in 2017Q2. It increased, as 11 investors sold Esperion Therapeutics, Inc. shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported.

Ameritas holds 1,310 shares or 0% of its portfolio. Moreover, Nationwide Fund Advisors has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 794 shares. Caisse De Depot Et Placement Du Quebec invested in 0.03% or 250,000 shares. Virtu Fincl Limited Liability has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Voya Invest Mgmt Limited Co has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Columbus Circle Invsts reported 0.04% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Renaissance Tech Limited Liability reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). 880,323 were reported by Vanguard. Us Natl Bank De has 11,051 shares. Atika Mgmt Llc holds 0.2% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 13,700 shares. The Illinois-based Pentwater Mgmt Lp has invested 0.96% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Moore Cap Management Lp holds 0.04% or 45,000 shares in its portfolio. Parkside National Bank Trust invested in 0.02% or 900 shares. Great West Life Assurance Can holds 0% or 1,300 shares.

The New Bb Biotech Ag Holding in Esperion Therapeutics, Inc

Bb Biotech Ag reported SC 13G/A form with the SEC for Esperion Therapeutics, Inc. Access it here: 000119312518045532. As reported by Bb Biotech Ag, the filler owns 9% or 2,362,964 shares of the Health Care–company.

Esperion Therapeutics, Inc stake is new for [reportingPerson]. Date of activity: December31, 2017. This shows Bb Biotech Ag’s positive view for Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc Institutional Sentiment

Filings show 114 investors own Esperion Therapeutics, Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 8344470. 25065133 were owned by these investors. 24 funds opened new Esperion Therapeutics, Inc stakes, 48 increased positions. There were 53 that closed positions and 30 reduced them.

2 investors had the stock in their top 10. Some are: Iguana Healthcare Management Llc, Meditor Group Ltd, Aisling Capital Llc..

Matthew Halbower Pentwater Capital Management Lp is an investor bullish on Esperion Therapeutics, Inc, owning 1450000 shares as of Q3 2015 for 0.30% of its portfolio. First Light Asset Management Llc owns 47965 shares or 0.56% of its portfolio. CT Sarissa Capital Management Lp have 2.61% of its portfolio for 448000 shares. Further, Bb Biotech Ag reported stake worth 0.68% of its portfolio. The NY Aisling Capital Llc owns 1637125 shares. Esperion Therapeutics, Inc is 6.79% of its portfolio.

Business Profile

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

SEC Form 13G.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on February, 28. They expect $-1.80 EPS, down 39.53 % or $0.51 from last year’s $-1.29 per share. After $-1.86 actual EPS reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -3.23 % EPS growth.

The stock increased 1.82% or $1.34 during the last trading session, reaching $75.1. About 280,602 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since February 15, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.97 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Esperion Therapeutics has $130.0 highest and $10 lowest target. $55.18’s average target is -26.52% below currents $75.1 stock price. Esperion Therapeutics had 53 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Buy” rating by Needham given on Monday, August 10. The company was maintained on Tuesday, December 15 by RBC Capital Markets. On Friday, September 4 the stock rating was downgraded by Zacks to “Hold”. The firm has “Equal-Weight” rating by Barclays Capital given on Wednesday, June 29. The firm has “Buy” rating by WallachBeth Capital given on Monday, October 26. The company was upgraded on Wednesday, August 19 by Needham. The company was maintained on Thursday, February 25 by Stifel Nicolaus. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, February 24 report. Stifel Nicolaus maintained the shares of ESPR in report on Monday, January 15 with “Buy” rating. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Outperform” rating given on Friday, November 6 by RBC Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.